Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Aardvark Therapeutics announced the termination of its Phase 3 HERO and OLE trials for ARD-101 in Prader-Willi Syndrome following a full clinical hold imposed by the FDA. The company is currently assessing unblinded trial data to decide on next steps. It reported a net loss of $14.4 million for Q2 2026 with a cash runway expected into late 2027.